Anatol J Cardiol, Vol: 21, Supplement: 1, March 2019

Dear friends and colleagues,

Natriuretic peptides are currently widely used biomarkers and provide useful information in the diagnosis, prognosis and risk stratification in heart failure. These biomarkers are not only used in the management of heart failure, but also natriuretic peptides are referred to have potential role in pulmonary arterial hypertension, cardio-oncology, advanced heart failure, assessment of response to cardiac resynchronization therapy, acute coronary syndromes, atrial fibrillation and valvular heart disease. In this paper, updated information and new recommendations on natriuretic peptides in heart failure and also potential role of these biomarkers in the management of various clinical conditions have been addressed in the form of expert opinions based on the available data in the literature.

The present work as an initiative of Heart Failure Working Group of Turkish Society of Cardiology was written by the authors who have a broad range of expertise and experience in the field of heart failure, pulmonary arterial hypertension, arrhythmia, cardio-oncology, acute coronary syndromes and valvular heart diseases. This document is mainly focused on the clinical use of natriuretic peptides and intended for cardiologists, internists, cardiology trainees, general practitioners and nurses.

We hope you find this document helpful in clinical use of natriuretic peptides in your daily clinical practice.

Prof. Dr. Yüksel Çavuşoğlu, Fellow of the HFA, Fellow of the ESC
Special Issue Editor
Former Chairperson of TSC Heart Failure Working Group (2012-2014 and 2017-2018)
Eskişehir Osmangazi University, Faculty of Medicine, Cardiology Department, Eskişehir

Address for correspondence: Yüksel Çavuşoğlu, MD, FESC, Department of Cardiology, Faculty of Medicine, Eskişehir Osmangazi University, 26480, Eskişehir-*Turkey*
Phone: +90 222 239 29 79 E-mail: yukselc@ogu.edu.tr

DOI:10.14744/AnatolJCardiol.2019.54789